The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Everolimus for Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex

mTOR inhibitor therapy for SEGA tumors and other manifestations of tuberous sclerosis complex enabling tumor reduction without surgery

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Everolimus for Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex?

Everolimus is oral selective mTORC1 inhibitor with established efficacy across TSC manifestations.

Tuberous sclerosis complex involves TSC1 (hamartin) or TSC2 (tuberin) mutations causing mTOR pathway hyperactivation.

FDA approvals in TSC include SEGA, renal angiomyolipoma and refractory partial-onset seizures.

Pharmacokinetic monitoring with therapeutic trough levels typically 5-15 ng/mL guides dosing.

TSC affects multiple organs requiring comprehensive multidisciplinary surveillance and management.

Symptoms

Stomatitis and oral ulcerations are common requiring prophylactic dexamethasone mouthwash.
Infections including opportunistic infections require monitoring and prompt treatment.
Pneumonitis is potentially serious adverse effect requiring imaging and treatment modification.
Hyperlipidemia, hyperglycemia, transaminase elevations require monitoring with management.
Cytopenias including anemia, neutropenia, thrombocytopenia require periodic blood count monitoring.

Risk Factors

Tuberous sclerosis complex is autosomal dominant disorder with mutations in TSC1 or TSC2 genes.
Family history of TSC requires genetic counseling and surveillance of at-risk family members.
Severe malnutrition, immunosuppression, active infections require careful evaluation before initiation.
Pre-existing pulmonary disease increases pneumonitis risk requiring monitoring during therapy.
Concurrent strong CYP3A4 modulators significantly affect everolimus levels requiring dose adjustment.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • TSC diagnosis with SEGA tumors, renal angiomyolipomas or refractory seizures warrants everolimus consideration.
  • Multidisciplinary TSC care with neurology, urology, pulmonology, dermatology, genetics optimizes management.
  • New respiratory symptoms, fever, persistent infections require urgent evaluation for pneumonitis or infection.
  • Severe stomatitis interfering with nutrition, refractory hyperlipidemia or hyperglycemia require management.
  • Tumor regrowth or new TSC manifestations require imaging evaluation and treatment modification.

Treatment Methods

01
Everolimus dosing in SEGA targets trough 5-15 ng/mL with starting dose based on body surface area.
02
Therapeutic drug monitoring at week 2, 4, 8 then every 3-6 months guides dose adjustments.
03
Stomatitis prophylaxis with dexamethasone mouthwash significantly reduces oral toxicity.
04
Drug interaction management avoiding strong CYP3A4 inhibitors and inducers prevents toxicity.
05
Long-term continuous therapy with regular MRI surveillance, multidisciplinary TSC care, infection prophylaxis, metabolic monitoring with lipid and glucose management, growth monitoring in children, fertility counseling, and management of TSC manifestations across organ systems with surgery for refractory cases optimizes outcomes for patients with tuberous sclerosis complex.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.